Last update 21 Dec 2024

IACS-6274

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
IACS-006274, IACS-6274
Target
GLS
Mechanism
GLS inhibitors(Glutaminase inhibitors)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [2]
Active Indication
Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaChondrosarcoma+ [9]
Inactive Indication-
Originator Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Active Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with IACS-6274
NCT05039801 / RecruitingPhase 1IIT
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
100 Clinical Results associated with IACS-6274
Login to view more data
100 Translational Medicine associated with IACS-6274
Login to view more data
100 Patents (Medical) associated with IACS-6274
Login to view more data
100 Deals associated with IACS-6274
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Endometrial CarcinomaPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
Advanced Head and Neck Squamous Cell CarcinomaPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
ChondrosarcomaPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
Clear Cell AdenocarcinomaPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
high grade serous adenocarcinoma of ovaryPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
Melanoma, Cutaneous MalignantPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
Ovarian clear cell adenocarcinomaPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
Refractory Endometrial AdenocarcinomaPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
Refractory Head and Neck CarcinomaPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
Refractory MelanomaPhase 1
US
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
09 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free